# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian epithelial cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 71-80 of 535 results.
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Feb 21, 2020
First Received: Aug 28, 2019
Disease(s): Ovarian Cancer Recurrent
Intervention(s): Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin, Paclitaxel
Locations: Leiden University Medical Center, Leiden, ZH, Netherlands
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Status: Recruiting
Last Changed: Mar 19, 2020
First Received: Oct 04, 2018
Disease(s): OVARIAN CANCER
Intervention(s): Cobimetinib, Niraparib, Atezolizumab
Locations: University of Arizona Cancer Center, North, Tucson, Arizona, United States
Moores Cancer Center at UC San Diego Health, La Jolla, California, United States
Sutter Health, San Francisco, California, United States
Mayo Clinic-Jacksonville, Jacksonville, Florida, United States
Florida Hospital Cancer Institute; Clinical Research Department, Orlando, Florida, United States
... and 25 other locations.
Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
Status: Recruiting
Last Changed: Dec 05, 2019
First Received: Oct 14, 2016
Disease(s): Ovarian Cancer
Intervention(s): OncoImmunome
Locations: UConn Health, Farmington, Connecticut, United States
Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer
Status: Recruiting
Last Changed: Jul 05, 2019
First Received: Feb 28, 2018
Disease(s): Ovarian Cancer
Intervention(s): HIPEC
Locations: Ajou University Hospital, Suwon, Gyeonggi, Korea, Republic of
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Status: Recruiting
Last Changed: Dec 04, 2018
First Received: Dec 04, 2018
Disease(s): Ovarian Cancer
Intervention(s): Sevacizumab, Paclitaxel, Topotecan
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
The first affiliated hospital,sun yat-sen university, Guangzhou, Guangdong, China
the Affiliated Cancer Hospital of Harbin Medical University, Harbin, Hei Longjiang, China
Hunan Cancer Hospital, Changsha, Hunan, China
... and 2 other locations.
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
Status: Recruiting
Last Changed: Dec 17, 2019
First Received: Sep 12, 2017
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Cediranib
Locations: Calvary Mater Hospital, Sydney, New South Wales, Australia
Campbelltown Hospital, Sydney, New South Wales, Australia
Prince of Wales Hospital, Sydney, New South Wales, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
Border Medical Oncology, Albury, Australia
... and 29 other locations.
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)
Status: Recruiting
Last Changed: Sep 26, 2019
First Received: Jan 22, 2019
Disease(s): Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Intervention(s): 18F-DCFPyL
Locations: Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Status: Recruiting
Last Changed: Jan 10, 2020
First Received: Jul 27, 2018
Disease(s): Ovarian Cancer
Intervention(s): Niraparib, Dostarlimab (TSR-042), Placebo
Locations: Alaska Women's Cancer Care, Anchorage, Alaska, United States
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Hartford Hospital, Hartford, Connecticut, United States
University of Florida Health Cancer Center, Gainesville, Florida, United States
Cancer Specialists of North Florida, Jacksonville, Florida, United States
... and 134 other locations.
Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jan 31, 2019
First Received: Oct 02, 2018
Disease(s): Epithelial Ovarian Cancer
Intervention(s): anti-Mesothelin Car NK Cells
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Status: Recruiting
Last Changed: Oct 17, 2018
First Received: Oct 17, 2018
Disease(s): Ovarian Cancer
Intervention(s): ZL-2306 (Nirapairb), Placebo Comparator
Locations: Anhui Provincal Hospital, Hefei, Anhui, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Guizhou Cancer hospital, Guiyang, Guizhou, China
... and 26 other locations.